The Alzheimer’s Drug Discovery Foundation (ADDF) announced on October 28, 2026 that Eli Lilly and Company has licensed SpeechDx, a longitudinal speech-and-biomarker dataset built by the foundation’s Diagnostics Accelerator, and will use the resource to study whether speech can serve as a tool for Alzheimer’s research. Lilly is the third organization to license the dataset, joining Siemens Healthineers and Callyope. The foundation characterizes SpeechDx as the largest harmonized longitudinal…